This is despite a statistical difference between early (19.2 months) and late groups (3.9 months, P < .001) for EGFR-mt patients.14 Although the cause of this difference remains undetermined, it may be due to the fact that EGFR-wt NSCLC patients develop BMs in the final stages of the disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.